Patents by Inventor Mauro Moroni

Mauro Moroni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of carotenoid derivatives to reduce the toxicity and increase the efficacy of anti-EGFR antitumor treatments
    Patent number: 11318108
    Abstract: The present invention refers to compounds of the carotenoid class, such as lycopene or lacto-lycopene, for their use in the treatment and/or prevention of toxicity caused by antitumor drugs, as well as their use in the treatment or remission of tumors in combination with antitumor drugs. Finally, the present invention refers to the combination of the above set forth compounds and drugs with antitumor action.
    Type: Grant
    Filed: January 15, 2018
    Date of Patent: May 3, 2022
    Assignee: ASSOCIAZIONE ONCOLOGICA MILANESE AMO LA VITA ONLUS
    Inventors: Mauro Moroni, Paolo Pedrazzoli, Marco Giulio Giuseppe Pirovano
  • USE OF CAROTENOID DERIVATIVES TO REDUCE THE TOXICITY AND INCREASE THE EFFICACY OF ANTI-EGFR ANTITUMOR TREATMENTS
    Publication number: 20210128491
    Abstract: The present invention refers to compounds of the carotenoid class, such as lycopene or lacto-lycopene, for their use in the treatment and/or prevention of toxicity caused by antitumor drugs, as well as their use in the treatment or remission of tumors in combination with antitumor drugs. Finally, the present invention refers to the combination of the above set forth compounds and drugs with antitumor action.
    Type: Application
    Filed: January 15, 2018
    Publication date: May 6, 2021
    Inventors: Mauro MORONI, Paolo PEDRAZZOLI, Marco Giulio Giuseppe PIROVANO
  • Epidermal growth factor receptor gene copy number
    Patent number: 7635570
    Abstract: Methods of predicting whether an anti-epidermal growth factor receptor (“EGFr”)-specific binding agent treatment will be efficacious in treating cancer, and methods of treating patients with anti-EGFr-specific binding agents, are provided.
    Type: Grant
    Filed: March 30, 2006
    Date of Patent: December 22, 2009
    Inventors: Salvatore Siena, Mauro Moroni, Alberto Bardelli
  • Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
    Publication number: 20090269344
    Abstract: The invention relates to an indidualized and personalized diagnosis and therapy of cancer based on specific molecular alterations which occur in specific tumor tissue of specific tumor patient populations. The therapy and diagnostic is based on the findings that proliferation and tumor growth of specific EGFR bearing tumor tissue expressing an amplified EGFR gene copy number may be abolished by anti-EGFR antibodies, while other individual molecular alterations such as mutations occurring in tumor tissues are unaffected by the same anti-EGFR antibody treatment.
    Type: Application
    Filed: April 12, 2006
    Publication date: October 29, 2009
    Inventors: Salvatore Siena, Mauro Moroni, Giovanna Marrapese, Andrea Sartore-Bianchi, Silvio Veronese, Marcello Gambacorta, Silvia Benvenuti, Federica Di Nicolantonio, Alberto Bardelli
  • Epidermal growth factor receptor gene copy number
    Publication number: 20070087394
    Abstract: Methods of predicting whether an anti-epidermal growth factor receptor (“EGFr”)-specific binding agent treatment will be efficacious in treating cancer, and methods of treating patients with anti-EGFr-specific binding agents, are provided.
    Type: Application
    Filed: March 30, 2006
    Publication date: April 19, 2007
    Inventors: Salvatore Siena, Mauro Moroni, Alberto Bardelli